Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Cyclooxygenase-2 negatively regulates innate lymphoid cell type 2 differentiation and function during allergic lung inflammation
Hong Li, Matthew L. Edin, Daniel Menendez, J. Alyce Bradbury, Joan P. Graves, Artiom Gruzdev, Gregory S. Whitehead, Maria I. Sifre, Laura M. DeGraff, Darryl C. Zeldin
Hong Li, Matthew L. Edin, Daniel Menendez, J. Alyce Bradbury, Joan P. Graves, Artiom Gruzdev, Gregory S. Whitehead, Maria I. Sifre, Laura M. DeGraff, Darryl C. Zeldin
View: Text | PDF
Research Article Immunology Pulmonology

Cyclooxygenase-2 negatively regulates innate lymphoid cell type 2 differentiation and function during allergic lung inflammation

  • Text
  • PDF
Abstract

Type 2 innate lymphoid cells (ILC2) are a population of lineage-negative cells in the lung, gastrointestinal tract, and skin that have emerged as a significant component of type 2 allergic inflammation. The regulation of cyclooxygenase-2 (COX-2) metabolites is critical to the pathophysiology of many inflammatory disorders, including allergic asthma. While COX-2 regulates Th9 and Th17 cell differentiation and function during allergic lung inflammation, it remains unknown whether COX-2 also regulates ILC2 cell differentiation and function under similar conditions. To address this question, we examined lung ILC2 cells from COX-2+/+ and COX-2–/– mice after ovalbumin-induced (OVA-induced) or Alternaria-induced allergic lung inflammation. ILC2 cells were significantly increased in COX-2–/– lungs compared with COX-2+/+ lungs after OVA exposure in vivo. The increase in ILC2 cells was accompanied by an increase in expression of the cytokines IL-5 and IL-13 and of the transcription factor GATA3. Both genetic disruption and selective inhibition of COX-2 significantly increased ILC2 cell differentiation from isolated common lymphoid progenitor cells (CLP) in vitro. Furthermore, COX-2–derived PGE2 acting via EP2 receptors significantly reduced IL-33 and TSLP expression, and it attenuated ILC2 cell differentiation in vitro and in vivo. Thus, during allergic lung inflammation, COX-2–derived PGE2 signals through the EP2 receptor to negatively regulate lung ILC2 cell differentiation and function.

Authors

Hong Li, Matthew L. Edin, Daniel Menendez, J. Alyce Bradbury, Joan P. Graves, Artiom Gruzdev, Gregory S. Whitehead, Maria I. Sifre, Laura M. DeGraff, Darryl C. Zeldin

×

Figure 1

COX-2–/– lungs have increased ILC2 cells during allergic inflammation induced by OVA and Alternaria in vivo.

Options: View larger image (or click on image) Download as PowerPoint

COX-2–/– lungs have increased ILC2 cells during allergic inflammation i...
(A) Schematic of the in vivo allergic lung inflammation models used. COX-2+/+ and COX-2–/– mice were sensitized to OVA in the presence of adjuvant (Alum) via i.p. injection (Days 0 and 1) and then exposed to 1% OVA via aerosol for 5 consecutive days (Day 14 to 18). Alternatively, mice were exposed to Alternaria extract by i.n. injection (20 μg/mouse/day) for 4 days. Mice were sacrificed 24 hours after the last exposure and lungs were collected for analysis. (B) ILC2 cells as a percentage of CD45+Lin– cells were quantified by FACS in lungs from vehicle- and OVA-treated COX-2+/+ and COX-2–/– mice (n = 5 per group, *P < 0.05). (C) Representative FACS plots of OVA-treated COX-2+/+ and COX-2–/– lungs showing ILC2 cells (GATA3+ CD11b–). (D) IL-5+, IL-13+, and GATA3+ ILC2 cells as a percentage of CD90+KLRG1+ cells in lungs from OVA-treated COX-2+/+ and COX-2–/– mice were quantified by FACS analysis. (E) After PBS or Alternaria exposure, ILC2 cells as a percentage of CD45+Lin– cells, or IL-5+, IL-13+, and GATA3+ ILC2 cells as a percentage of CD90+KLRG1+ cells in lungs from COX-2+/+ and COX-2–/– mice were quantified by FACS analysis. n = 3–5/group, *P < 0.05 by 2-way ANOVA.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts